miR‑5590‑3p inhibits the proliferation and metastasis of renal cancer cells by targeting ROCK2 to inhibit proliferation, migration and invasion

Liu,Queling; Zhu,Anyi; Gao,Weiyin; Gui,Fu; Zou,Yan; Zhou,Xiaocheng; Hong,Zhengdong

doi:10.3892/ol.2022.13497

miR‑5590‑3p inhibits the proliferation and metastasis of renal cancer cells by targeting ROCK2 to inhibit proliferation, migration and invasion

Authors:
- Queling Liu
- Anyi Zhu
- Weiyin Gao
- Fu Gui
- Yan Zou
- Xiaocheng Zhou
- Zhengdong Hong
View Affiliations

Affiliations: Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Ophthalmology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: September 8, 2022 https://doi.org/10.3892/ol.2022.13497
Article Number: 377
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to clarify the role of microRNA (miR)‑5590‑3p in the progression of renal cell carcinoma (RCC) and investigate the underlying mechanisms. The expression levels of miR‑5590‑3p, Rho‑associated protein kinase (ROCK)2 and β‑catenin in RCC cells were measured by reverse transcription‑quantitative PCR and western blot analysis. Following overexpression of miR‑5590‑3p and ROCK2 by transfection of miR‑5590‑3p mimics and GV367‑ROCK2, respectively, changes in the proliferation, migration and invasion of RCC cells were determined through colony‑formation, wound‑healing and Transwell assays, respectively. The direct binding interaction between miR‑5590‑3p and ROCK2, initially predicted using Targetscan, was validated by a dual‑luciferase reporter assay. The results indicated that miR‑5590‑3p was downregulated in RCC. Overexpression of miR‑5590‑3p led to downregulation of ROCK2 and β‑catenin and inhibited the proliferation, migration and invasion of RCC cells. The dual‑luciferase reporter assay confirmed the binding relationship between miR‑5590‑3p and ROCK2. Of note, overexpression of ROCK2 effectively reversed the regulatory effects of miR‑5590‑3p on RCC cells. In conclusion, miR‑5590‑3p inhibits the proliferation, migration and invasion of RCC cells by targeting ROCK2, which is a potential molecular biomarker and therapeutic target for RCC.

View Figures

View References

1	Koul H, Huh JS, Rove KO, Crompton L, Koul S, Meacham RB and Kim FJ: Molecular aspects of renal cell carcinoma: A review. Am J Cancer Res. 1:240–254. 2011.PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Ahrens M, Scheich S, Hartmann A and Bergmann L; IAG-N Interdisciplinary Working Group Kidney Cancer of the German Cancer Society, : Non-clear cell renal cell carcinoma-pathology and treatment options. Oncol Res Treat. 42:128–135. 2019. View Article : Google Scholar : PubMed/NCBI
4	Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C and Russo P: Epidemiology of Renal Cell Carcinoma. Eur Urol. 75:74–84. 2019. View Article : Google Scholar : PubMed/NCBI
5	Bruchbacher A, Lemberger U, Hassler MR, Fajkovic H and Schmidinger M: PD1/PD-L1 therapy in metastatic renal cell carcinoma. Curr Opin Urol. 30:534–541. 2020. View Article : Google Scholar : PubMed/NCBI
6	Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Lam TB, Ljungberg B, Marconi L, Klatte T, Volpe A, et al: Updated European Association of Urology guidelines on renal cell carcinoma: Nivolumab plus cabozantinib joins immune checkpoint inhibition combination Therapies for treatment-naive metastatic clear-cell renal cell carcinoma. Eur Urol. 79:339–342. 2021. View Article : Google Scholar : PubMed/NCBI
7	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
8	Yang L, Zou X, Zou J and Zhang G: A review of recent research on the role of MicroRNAs in renal cancer. Med Sci Monit. 27:e9306392021. View Article : Google Scholar : PubMed/NCBI
9	Maher ER: Hereditary renal cell carcinoma syndromes: Diagnosis, surveillance and management. World J Urol. 36:1891–1898. 2018. View Article : Google Scholar : PubMed/NCBI
10	Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, et al: Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 43:1022–1025. 2011. View Article : Google Scholar : PubMed/NCBI
11	Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, et al: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 16:68–73. 1997. View Article : Google Scholar : PubMed/NCBI
12	Huang G, Lai Y, Pan X, Zhou L, Quan J, Zhao L, Li Z, Lin C, Wang J, Li H, et al: Tumor suppressor miR-33b-5p regulates cellular function and acts a prognostic biomarker in RCC. Am J Transl Res. 12:3346–3360. 2020.PubMed/NCBI
13	Chen FY, Zhou ZY, Zhang KJ, Pang J and Wang SM: Long non-coding RNA MIR100HG promotes the migration, invasion and proliferation of triple-negative breast cancer cells by targeting the miR-5590-3p/OTX1 axis. Cancer Cell Int. 20:5082020. View Article : Google Scholar : PubMed/NCBI
14	Luo ZF, Peng Y, Liu FH, Ma JS, Hu G, Lai SL, Lin H, Chen JJ, Zou GM, Yan Q and Sui WG: Long noncoding RNA SNHG14 promotes malignancy of prostate cancer by regulating with miR-5590-3p/YY1 axis. Eur Rev Med Pharmacol Sci. 24:4697–4709. 2020.PubMed/NCBI
15	Wu N, Han Y, Liu H, Jiang M, Chu Y, Cao J, Lin J, Liu Y, Xu B and Xie X: MiR-5590-3p inhibited tumor growth in gastric cancer by targeting DDX5/AKT/m-TOR pathway. Biochem Biophys Res Commun. 503:1491–1497. 2018. View Article : Google Scholar : PubMed/NCBI
16	Yang Y, Dong MH, Hu HM, Min QH and Xiao L: LncRNA FGD5-AS1/miR-5590-3p axis facilitates the proliferation and metastasis of renal cell carcinoma through ERK/AKT signalling. Eur Rev Med Pharmacol Sci. 24:8756–8766. 2020.PubMed/NCBI
17	Sharma P and Roy K: ROCK-2-selective targeting and its therapeutic outcomes. Drug Discov Today. 25:446–455. 2020. View Article : Google Scholar : PubMed/NCBI
18	Wei L, Surma M, Shi S, Lambert-Cheatham N and Shi J: Novel insights into the roles of rho kinase in cancer. Arch Immunol Ther Exp (Warsz). 64:259–278. 2016. View Article : Google Scholar : PubMed/NCBI
19	de Sousa GR, Vieira GM, das Chagas PF, Pezuk JA and Brassesco MS: Should we keep rocking? Portraits from targeting Rho kinases in cancer. Pharmacol Res. 160:1050932020. View Article : Google Scholar : PubMed/NCBI
20	Xu Z, Hong Z, Ma M, Liu X, Chen L, Zheng C, Xi X and Shao J: Rock2 promotes RCC proliferation by decreasing SCARA5 expression through β-catenin/TCF4 signaling. Biochem Biophys Res Commun. 480:586–593. 2016. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G, Cimadamore A, Santoni M, Fiorentino M, Montironi R and Massari F: The molecular characteristics of non-clear cell renal cell carcinoma: What's the story morning glory? Int J Mol Sci. 22:62372021. View Article : Google Scholar : PubMed/NCBI
23	Sharma R, Kadife E, Myers M, Kannourakis G, Prithviraj P and Ahmed N: Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. J Exp Clin Cancer Res. 40:1862021. View Article : Google Scholar : PubMed/NCBI
24	Mlcochova H, Machackova T, Rabien A, Radova L, Fabian P, Iliev R, Slaba K, Poprach A, Kilic E, Stanik M, et al: Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma. Sci Rep. 6:318522016. View Article : Google Scholar : PubMed/NCBI
25	Bhat S: Role of surgery in advanced/metastatic renal cell carcinoma. Indian J Urol. 26:167–176. 2010. View Article : Google Scholar : PubMed/NCBI
26	Winter J, Jung S, Keller S, Gregory RI and Diederichs S: Many roads to maturity: MicroRNA biogenesis pathways and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
27	Çaykara B, Ozturk G, Alsaadoni H, Otunctemur A and Pence S: Evaluation of MicroRNA-124 expression in renal cell carcinoma. Balkan J Med Genet. 23:73–78. 2021. View Article : Google Scholar : PubMed/NCBI
28	He X, Liao S, Lu D, Zhang F, Sun Y and Wu Y: MiR-125b promotes migration and invasion by targeting the vitamin D receptor in renal cell carcinoma. Int J Med Sci. 18:150–156. 2021. View Article : Google Scholar : PubMed/NCBI
29	Cheng C, Guo L, Ma Y, Wang Z, Fan X and Shan Z: Up-Regulation of miR-26a-5p Inhibits E2F7 to regulate the progression of renal carcinoma cells. Cancer Manag Res. 12:11723–11733. 2020. View Article : Google Scholar : PubMed/NCBI
30	Zhang W, Wu Y, Hou B, Wang Y, Deng D, Fu Z and Xu Z: A SOX9-AS1/miR-5590-3p/SOX9 positive feedback loop drives tumor growth and metastasis in hepatocellular carcinoma through the Wnt/β-catenin pathway. Mol Oncol. 13:2194–2210. 2019. View Article : Google Scholar : PubMed/NCBI
31	Yang Y, Dong MH, Hu HM, Min QH and Xiao L: LncRNA FGD5-AS1/miR-5590-3p axis facilitates the proliferation and metastasis of renal cell carcinoma through ERK/AKT signalling. Eur Rev Med Pharmacol Sci. 24:8756–8766. 2020.PubMed/NCBI
32	Du Y, Lu S, Ge J, Long D, Wen C, Tan S, Chen L and Zhou W: ROCK2 disturbs MKP1 expression to promote invasion and metastasis in hepatocellular carcinoma. Am J Cancer Res. 10:884–896. 2020.PubMed/NCBI
33	Deng X, Yi X, Huang D, Liu P, Chen L, Du Y and Hao L: ROCK2 mediates osteosarcoma progression and TRAIL resistance by modulating O-GlcNAc transferase degradation. Am J Cancer Res. 10:781–798. 2020.PubMed/NCBI
34	Deng B, Deng J, Yi X, Zou Y and Li C: ROCK2 promotes osteosarcoma growth and glycolysis by up-regulating HKII via Phospho-PI3K/AKT signalling. Cancer Manag Res. 13:449–462. 2021. View Article : Google Scholar : PubMed/NCBI
35	Luo J, Lou Z and Zheng J: Targeted regulation by ROCK2 on bladder carcinoma via Wnt signaling under hypoxia. Cancer Biomark. 24:109–116. 2019. View Article : Google Scholar : PubMed/NCBI
36	Qiu Y, Yuan R, Zhang S, Chen L, Huang D, Hao H and Shao J: Rock2 stabilizes β-catenin to promote tumor invasion and metastasis in colorectal cancer. Biochem Biophys Res Commun. 467:629–637. 2015. View Article : Google Scholar : PubMed/NCBI
37	Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al: AJCC Cancer Staging Manual. 8th edition. Springer; Berlin, Germany: pp. 79–81. 2017, PubMed/NCBI